Endothelial progenitor cells (EPCs) consist of two different subpopulations named early (eEPCs) and late EPCs (lEPCs) that are derived from CD14 + and CD14 − circulating cells, respectively. These cells are regularly cultured over fibronectin-coated surfaces in endothelial basal medium (EBM)-2 supplemented with insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF). We have developed a new and simplified method for culturing human EPCs obtained from peripheral blood and tested their ability to preserve cardiac function following infarction. We first demonstrated that eEPCs derived from human peripheral blood mononuclear cells (PBMCs) and cultured in EBM-2 medium supplemented with autologous serum (10%) over fibronectincoated surfaces (10 µg/ml) in the presence of IGF-1 (50 ng/ml) only, have a secretome similar to eEPCs cultured under regular conditions with IGF-1, VEGF, EGF, and FGF. Our data also indicate that IGF-1 modulates PBMC secretome in a dose-dependent manner. In another series of experiments, we showed that PBMCs cultured in suspension in bags (S-PBMCs) in basal medium supplemented with fibronectin and IGF-1 secrete significant amounts of stem cell factor (SCF, 31.3 ± 3.1 pg/ml)), hepatocyte growth factor (HGF, 438.6 ± 41.4 pg/ml), soluble tumor necrosis factor receptor 1 (sTNFR1, 127.1 ± 9.9 pg/ml), VEGF (139.3 ± 9.6 pg/ml), and IGF-1 (147.2 ± 46.1 pg/ml) but very low levels of TNF-α (13.4 ± 2.5 pg/ml). S-PBMCs injected intravenously into NOD SCID mice migrated to the injured myocardium, reduced cardiac fibrosis, enhanced angiogenesis, and preserved cardiac function after myocardial infarction (MI) in a manner similar to eEPCs cultured under standard conditions. In conclusion, we show in this study a refined and optimized method for culturing eEPCs. Our data indicate that S-PBMCs are composed of several cell populations including eEPCs and that they secrete high amounts of antiapoptotic, anti-inflammatory, and proangiogenic factors capable of preserving cardiac function following MI.
INTRODUCTION
ous endothelial properties (9, 12, 21) . Controversy exists with respect to the identification and the origin of endothelial progenitor cells. Overall, there is consensus that Endothelial progenitor cells (EPCs) were first identified by Asahara et al. as a subset of CD34 + hematopoi-EPCs consist of two different subpopulations with different morphologies and growth patterns, termed early etic progenitor cells (3). EPCs are isolated from circulating mononuclear cells (3,25), bone marrow (27) , and and late EPCs. Early EPCs (eEPCs) are derived from CD14 + subpopulations of peripheral blood mononuclear cord blood (24) . They express antigens such as CD14, CD34, vascular endothelial growth factor receptor 2 cells (PBMCs) and exhibit a spindle-like morphology when cultured during 1 week under angiogenic condi-(VEGF-R2) and CD133 shared by hematopoietic stem cells together with endothelial cells and exhibit numer-tions. eEPCs virtually do not proliferate and are not able 1432 BOUCHENTOUF ET AL.
to form vascular structures in vitro (12, 26, 35, 39) . Late CD56 antibodies used for fluorescence activated cell sorting (FACS) were obtained from R&D Systems EPCs (lEPCs) are derived from CD14 − fraction. They exhibit cobblestone morphology after 3-4 weeks of cul-(Minneapolis, MI, USA). EBM-2, human (h)EGF, human FGF, VEGF, and IGF-1 were from Lonza ture under angiogenic conditions. lEPCs form vascular networks in vitro and in vivo (12, 39) .
(Walkersville, MD, USA). ELISA for cardiac troponin I (cTNI) was from Life Diagnostics (Westchester, PA, EPCs have been investigated as a new strategy in regenerative medicine for ischemic diseases. Several clini-USA). RPMI was purchased from Hyclone (Logan, UT, USA). Permalife cell culture bags were from Origen cal trials have been performed following the promising results obtained in animal models of ischemia-induced (Helsingborg, Sweden). cardiovascular injury (8, 15, 16) . In one study, autologous Cell Isolation and Culture AC133 + bone marrow cells were injected into tissue adjacent to the ischemic area during coronary artery by-Human PBMCs were obtained by Ficoll gradient separation of healthy donor apheresis. The continuous flow pass surgery in six patients who had suffered a myocardial infarction (MI). The procedure enhanced the global cell separator machine COBE Spectra Version 6.1 (COBE Laboratories, Lakewood, CO, USA) was used to left ventricular function and improved infarcted tissue perfusion (31) . Transplantation Of Progenitor Cells And collect white blood cells from peripheral blood as previously reported. The machine was set up and primed Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) investigators reported greater according to the manufacturer's instructions. Bilateral peripheral venous access via a basilic or cephalic vein left ventricular ejection fraction (LVEF) and viability following intracoronary injection of bone marrow-derived was used to perform the collection and low molecular weight heparin was used as the anticoagulant. This com-cells and circulating progenitor cells in a group of patients (29). Interestingly, there was no difference be-pletely automated procedure is based on parameters entered at the start of the procedure (hematocrit, weight, tween groups in the TOPCARE-AMI study in which patients were treated with bone marrow-derived cells or and height). Usually, two times total blood volume is processed over approximately 3-4 h at a rate of less circulating progenitor cells, suggesting that both cell populations may be equipotent in their ability to im-than 65 ml/min. No prior mobilization regimens were given. The cells were harvested into the collection bag prove myocardial function after an MI. In the BOne marrOw transfer to enhance ST-elevation infarct regen-and used for study purposes. The study was approved by the Royal Victoria Hospital ethics committee (McGill eration (BOOST) trial, accelerated LVEF recovery after an MI was found following bone marrow cell injection University Heath Centre) and a signed informed consent was obtained from each participant. PBMCs were either and coronary intervention (23). eEPCs are typically cultured for 1 week in fibronec-seeded in T75 flasks (regular adherence condition) or cultured in suspension in 30-ml bags. Medium used to tin-coated surfaces in endothelial basal medium (EBM)-2 supplemented with VEGF, insulin like growth factor culture eEPCs consisted of EBM-2 supplemented with 10% autologous human serum, 1% Pen/Strep, 0.04% hy-(IGF-1), epidermal growth factor (EGF), and fibroblast growth factor (FGF) (2,5, 14, 17, 19, 30, 33, 37) . eEPC-adher-drocortisone, 0.1% heparin, and 0.1% ascorbic acid in presence of IGF-1 (50 ng/ml unless otherwise indi-ent culture production protocols are cumbersome and typically require specialized infrastructure and person-cated), EGF (10 ng/ml), FGF (50 ng/ml), VEGF (50 ng/ ml), and fibronectin (10 µg/ml unless otherwise indi-nel, limiting widespread use. In an effort to simplify eEPC production while retaining therapeutic potency, cated). Monocytes were isolated using the EasySep human monocyte purification kit (Stemcell Technologies, we refined the method of eEPC culture. Here, we show that PBMCs cultured in suspension in bags (S-PBMCs) Vancouver, BC, Canada) and cultured under adherence conditions in RPMI-based medium supplemented with in EBM-2 supplemented only with fibronectin and IGF-1, secrete antiapoptotic, anti-inflammatory, and proangi-10% donor serum, 1% HEPES, 1% sodium pyruvate, and 1% Pen/Strep. For cells cultured under adherence ogenic factors that we show have a positive impact on cardiac function and remodeling following MI.
conditions (eEPCs and monocytes), medium was changed at day 3 following cell separation and was then changed each day. For cells cultured in suspension (S-
MATERIALS AND METHODS
PBMCs) no medium change was performed. Cells were Reagents kept in culture for 3 days (S-PBMCs) or 1 week (eEPCs ELISAs for tumor necrosis factor (TNF)-α, stem cell and monocytes) at 37°C in a tissue culture incubator factor (SCF), VEGF, soluble TNF receptor (sTNF-R)-1, (5% CO 2 ). Human serum was prepared by incubating IGF-1, and hepatocyte growth factor (HGF) as well as donor plasma supplemented with CaCl 2 (20 mM) at anti-CD4, anti-CD8, anti-CD14, anti-CD34, and anti-37°C under 5% CO 2 for 3-4 h. week under angiogenic conditions. (A) Peripheral blood mononuclear cells (PBMCs) were isolated from apheresis obtained from healthy donors using Ficoll gradient. Some cells were cultured either with insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), or epidermal growth factor (EGF). Some cells were cultured with all the above-mentioned growth factors [early endothelial progenitor cell (eEPC) group]. Purified monocytes (Mono) were cultured without any growth factor and were used as control. (B-G) Concentration of tumor necrosis factor-α (TNF-α), stem cell factor (SCF), VEGF, soluble TNF receptor 1 (sTNFR1), IGF-1, and hepatocyte growth factor (HGF) in the conditioned medium of each cell preparation reported in pg/ml/10 6 cells/24 h. Results are normalized to the concentration of cytokines and growth factors in the cell-free medium. Data are reported as mean ± SEM (n = 3). *,#Statistically significant difference between groups with the same symbol: p < 0.05. 
Enzyme-Linked Immunosorbent Assay (ELISA)
conform to the US National Institutes of Health Guide for the Care and Use of Laboratory Animals. In vivo ELISA was performed on eEPC-, S-PBMC-, and experiments were performed in eight NOD.CB17monocyte-conditioned media following the supplier pro-Prkdc scid [also known as nonobese diabetic severe comtocol. Data are normalized to the number of CD14 + cells bined immunodeficient (NOD SCID)] mice per group. in each population and are reported in pg/ml/10 6 cells/ MI was induced by ligation of left anterior descending 24 h. coronary artery as previously described. Previous publications demonstrated that injection of purified monocyte Cell Labeling for FACS Analysis derivatives have major regenerative properties by secre-Cells were resuspended in PBS containing 1% fetal ting growth factors, cytokines, and metalloproteinases bovine serum (FBS) buffer and incubated with phycoer-(MMPs) (5,11,28). Based on the FACS analysis for the ythrin (PE)-or fluorescein isothiocyanate (FITC)-conju-CD14 marker, PKH26-labeled eEPCs and S-PBMCs gated antibodies for 2 h at 4°C. FACS was performed were resuspended in PBS for injection respectively at a using a FACScalibur analyzer (BD Bioscience).
concentration of 3 × 10 4 and 10 5 cells/µl of PBS to compare equicellular amounts of CD14 + cells in both cell Animal Models preparations. A total of 6 × 10 5 eEPCs or 2 × 10 6 S-All experiments were carried out in agreement with PBMCs, or the equivalent PBS volume, were injected 6 local guidelines for the care and use of laboratory anidays after MI per mouse through the jugular vein with mals and in accordance with the guidelines of the Mca nontraumatic 30-and 27-gauge needle, respectively Gill University animal care authority. Investigations (Hamilton, USA).
Criteria of Inclusion and Exclusion in the MI Study
707B High Frame Rate Scanhead with a center frequency of 30 MHz. The percentages of isoflurane and Results presented in this study include mice with the O 2 flow were adjusted to obtain the fastest heart rate same heart rate and similar infarct sizes. The infarct size (HR) possible. Left ventricle (LV) end-diastolic and was estimated by determination by ELISA of cardiac end-systolic internal diameter (LVIDd and LVIDs), endtroponin I (cTnI) in mouse plasma collected 24 post-MI diastolic interventricular and LV posterior wall thickas previously described (7, 22) . Analysis of echocardioness (IVSd and LVPWd), and fractional shortening (FS) grams and study of myocardial histology were perwere determined as described previously (1,13). formed on mice with heart rates of 564 ± 18.6 bpm and a cTnI concentration of 30.2 ± 2.2 ng/ml.
Heart Dissection and Histological Analysis of EPC Migration Echocardiography
Mice were anesthetized with isofurane and a cut was made in the peritoneum to localize the posterior vena Echocardiography was performed as described previously with some modifications, 1 month after the in-cava (PVC). Eight hundred microliters of 0.1 M KCl was injected through the PVC to stop the heart in dias-duction of MI. Two-dimensional guided M-mode echocardiography was performed under light isoflurane tole. An incision was performed over the left thoracic area. Muscles over the ribs were delicately separated to anesthesia (0.75-1% isoflurane, 1 L/min O 2 ) using a Visual Sonic VEVO 770 ultrasound machine and a RMV TM visualize the heart. Pericardium was carefully opened and the heart was removed. Harvested hearts were then were then labeled with DAPI and observed using a Leica DM-LB2 microscope. injected with 0.5 ml of PBS/1% heparin via the superior vena cava. For the evaluation of the migration of eEPCs Statistical Analysis or S-PBMCs to the injured myocardium, hearts were mounted in OCT and sectioned at the histology facility Data are presented as means ± SEM. Differences among groups were statistically analyzed using analysis of Immunology and Cancer Research Institute of the University of Montreal (QC, Canada). Frozen sections of variance (ANOVA). Tests were followed up by Bon-ferroni correction within groups. Statistical analyses IGF-1. Our data indicate that fibronectin modulates the PBMC secretomes and that the optimal concentration of were performed using GraphPad software. A value of p < 0.05 was considered significant.
fibronectin was 10 µg/ml (Fig. 3) .
RESULTS

S-PBMCs Secrete Anti-inflammatory, Antiapoptotic, and Proangiogenic Factors IGF-1 Is Required to Induce eEPC Differentiation
In another series of experiments we investigated the eEPCs are commonly cultured in EBM-2 medium secretome of PBMCs cultured in suspension with 50 ng/ supplemented with IGF-1, VEGF, FGF, and EGF. In a ml IGF-1 and 10 µg/ml fibronectin in bags (S-PBMCs) first experiment, we evaluated whether all these growth compared to eEPCs cultured under regular conditions, factors were required to induce eEPC differentiation. and monocytes (Fig. 4A ). We compared equicellular eEPCs derived from peripheral blood share several amounts of CD14 + cells in eEPC and S-PBMC preparamarkers with myelomonocytic cells but have different tions. Our results indicate that S-PBMCs secreted, in 24 secretome profiles (6,27). Therefore, we cultured PBMCs h, 31.3 ± 3.1 pg/ml of SCF, 139.3 ± 9.6 pg/ml of VEGF, for 1 week in fibronectin-coated flasks with either IGF-127.1 ± 9.9 pg/ml of sTNFR1, 147.2 ± 46.1 pg/ml of 1, VEGF, FGF, or EGF and analyzed their secretome IGF-1, and 438.6 ± 41.4 pg/ml of HGF. The levels of relative to eEPCs cultured in presence of all four growth growth factors and cytokines secreted normalized to the factors and to monocytes. Our results show that IGF-1 is number of CD14 + cell contained in the S-PBMC populacapable alone of inducing PBMCs to secrete significant tion were comparable to those produced by eEPCs examounts of growth factors and cytokines (Fig. 1) . PBMCs cept for VEGF and HGF. Indeed, eEPCs secreted 1.6-(10 6 ) cultured with IGF-1 secreted, in 24 h, 34.5 ± 4.2 and 3-fold more VEGF and HGF, respectively, than Spg/ml of SCF, 192.3 ± 17.3 pg/ml of VEGF, 143.2 ± PBMCs. 11.6 pg/ml of sTNFR1, 166.2 ± 7.9 pg/ml of IGF-1, and 1131 ± 276 pg/ml of HGF. Treatment of PBMCs with Intravenous Injection of S-PBMCs Preserved Cardiac IGF-1 inhibited TNF-α secretion. The levels of growth Function After MI factors and cytokines secreted by PBMCs cultured only
We first characterized the lymphomyeloid cell popuwith IGF-1 were comparable to those produced by lation in eEPCs and S-PBMCs. eEPCs were composed eEPCs cultured with all four growth factors. PBMCs of 93% CD14 + and 21% CD34 + cells whereas CD4 + , cultured with VEGF, FGF, or EGF secreted low levels CD8 + , and CD56 + cells were virtually absent. S-PBMCs of growth factors and cytokines in comparison with were composed of 58% CD4 + , 39% CD8 + , 32% CD14 + , eEPCs and PBMCs cultured with IGF-1. 22 .4% CD34 + , and 29% CD56 + cells (Fig. 5A ). Based IGF-1 Modulates the eEPC Secretome on FACS analysis for the CD14 marker, we treated NOD SCID mice with PKH26-labeled eEPCs and S-The aim of the study is to test a new and simplified PBMCs, respectively, at a concentration of 3 × 10 4 and method for culturing human eEPCs obtained from pe-10 5 cells/µl of PBS to compare equicellular amounts of ripheral blood. We identified the optimal concentration CD14 + cells in both cell preparations and evaluated the of IGF-1 to induce secretion of SCF, VEGF, sTNFR1, cardiac outcome. Figure 5B and C shows that injected IGF-1, and HGF. Basically, PBMCs were seeded in ficells migrated to the injured myocardium. There were bronectin-coated flasks in EBM-2 supplemented with threefold (p = 0.01) more S-PBMCs than eEPCs per different concentrations of IGF-1. Data presented in Fig- heart section, consistent with the amount of injected ure 2 indicate that IGF-1 modulates the PBMC secretcells. Injection of S-PBMCs reduced cardiac fibrosis ome in a dose-dependent manner. eEPCs are typically 2.8-fold (p = 0.02) ( Fig. 5D ) and enhanced the number cultured with 50 ng/ml of IGF-1 among other growth of capillaries in the border and scar zones 1.9-fold (p = factors. We thus evaluated whether lower doses of IGF-0.03) and 1.6-fold (p = 0.03), respectively, in compari-1 (25, 12.5, and 6.25 ng/ml) would affect eEPC secretson to the MI group (Fig. 5E, H) . Left ventricle fracome. Figure 2 indicates that concentration of IGF-1 nortional shortening (% LVFS) of NOD SCID mice injected mally used to culture eEPCs (50 ng/ml) corresponds to with S-PBMCs and eEPCs improved 44.2% (p = 0.001) the lowest dose to induce the secretion of growth, antiand 43.3% (p = 0.001), respectively, relative to the unapoptotic, and proangiogenic factors (optimal dose).
treated MI group (Fig. 5F, G) .
Fibronectin Modulates the eEPC Secretomes
DISCUSSION In order to verify whether fibronectin was required to induce eEPC differentiation, PBMCs were seeded in Neovascularization is a major challenge in tissue regeneration research. EPCs have been suggested to play flasks coated with fibronectin at different concentrations and cultured in EBM-2 supplemented with 50 ng/ml an important role in postnatal angiogenesis and arterio- genesis (6). Early reports described the isolation and CD14, CD31, and CD34 markers. Cells are cultured on fibronectin-coated plates in endothelial medium supple-culture of eEPCs from mononuclear cells. These cells possessed endothelial cell morphology and expressed mented with various "endothelial" growth factors such as IGF-1, VEGF, FGF, and EGF (3,5,25,35). eEPCs ob-hematopoietic and endothelial markers after 3-7 days in culture (32) . The regular procedure for preparation of tained after 1 week in culture under these conditions express high levels of the monocytic marker CD14. eEPCs eEPCs includes the use of adherence culture of PBMCs or applies immunomagnetic selection techniques using do not proliferate, consistent with their end-differenti- Data are reported as mean ± SD (n = 3). IGF-1, insulin-like growth factor-1; S-PBMCs, PBMCs cultured in suspension in bags.
ated state, but secrete potent proangiogenic and antiapo-can transdifferentiate into cardiomyocytes, mature endothelial cells, and smooth muscle cells in vivo (38). Flow ptotic factors such as VEGF, IGF-1, and HGF (5,26). Furthermore, several studies have demonstrated that re-cytometry analysis of eEPCs and S-PBMCs indicate that 1.3 × 10 5 or 1.4 × 10 6 CD34 + cells were contained in the cruited monocytes/macrophages regulate angiogenesis in the ischemic tissue (5,28). eEPCs and in the S-PBMCs preparation, respectively. However, injection of eEPCs and S-PBMCs into NOD We hypothesized that unfractionated PBMCs cultured in suspension (S-PBMCs) are equivalent to eEPCs SCID mice after MI improved % LVFS in a similar manner (44.2% and 43.3%, respectively), indicating that cultured under regular conditions and that their intravenous injection could preserve cardiac function following monocytes play a critical role in preserving cardiac function as well. The concept of monocytes being able MI. In an attempt to simplify the culture medium, we first demonstrated that fibronectin and IGF-1 are re-to contribute to angiogenesis is not novel. As early as 2003, Urbich and colleagues showed that EPCs have quired for differentiation of eEPCs while other growth factors (e.g., VEGF, EGF, and FGF) were not essential. distinct monocytic features, and EPCs can be cultured from CD14 + cells. In vivo, monocytes were shown to be Intravenous injection of S-PBMCs in NOD SCID mice reduced cardiac fibrosis, enhanced capillary density, and able to contribute to angiogenesis as EPCs (27) . Mononuclear cells other than EPCs contained in the PBMCs improved % LVFS in a manner similar to eEPCs. These data suggest that injected CD14 + cells played a major mix such as NK cells (CD56 + cells) and lymphocytes (CD4 + and CD8 + cells) can contribute as well to ische-role in preserving cardiac function following MI. Normalizing the number of CD14 + for the in vivo studies mic neovascularization by secreting angiogenic cytokines. increases CD34 + cell population as well. CD34 + contained in the S-PBMC mix may indeed play a significant Treatment with EPCs has been reported to enhance ischemic angiogenesis in both preclinical and clinical role in preserving cardiac function. Previous publications reported that human peripheral blood CD34 + cells studies (4, 11, 15, 18, 34) . As the results of large-scale clinical trials become available, it is essential to identify tions) and approved by regulatory agencies in several countries. We propose that intravenous S-PBMCs ad-ways to standardize and optimize the use of these cells, thereby providing clinicians with innovative personal-ministration for acute and chronic vascular insufficiency syndromes may improve clinical outcomes. ized cell therapy tools to promote preservation of ischemic tissue. The ease by which the cells can be obtained
